More insider selling than buying of Paragon 28 shares over the last year could be a red flag. However, high insider ownership could indicate the company's interest in all shareholders. Lack of recent insider transactions provides little insight.
CEO Albert DaCosta expressed satisfaction with the company's 20% net revenue growth for 2023 and optimism for the future, stating his excitement to continue the company's mission of improving foot and ankle patient outcomes in 2024 and beyond.
Investors seem ready to pay premium for Paragon 28 given its bright future growth prospects justifying high P/S ratio. The chance of a revenue dip appears far-off, reinforcing the unlikelihood of a major share price drop soon.
Despite insider sales and a Paragon 28 value decrease, high insider ownership is encouraging, indicating management's shareholder interest. Yet, no insider transactions and past year insider sales raise risks and concerns.
$Paragon 28(FNA.US)$Stock was setup for a squeeze tomorrow. 1 million shares sold short or about 13% of the float. I bought the last of the shares remaining 5 secs before market closed. The next bid was 34.00. But in come the cheaters. Not only did they do a prospectus after they just listed on Friday but their directors exercised their options.
On the last trading day, the Dow Jones Industrial Average rose1.09%. The S&P Index climbed0.75% and the Nasdaq Composite Index gained0.50%. On the last trading day, there were five traditional IPO filed, while one new stock officially was listed for trading. Medical device company Paragon 28 started trading yesterday. It soared 16.94% in its NYSE debut and was valued at $1.41 billion. Cloud-based expense management software platform$Expensify(EXFY.US)$, based in Portland, Oregon, helps the smallest to the largest businesses simplify the way they manage money. Since its founding in 2008, it has added over 10 million members to the community, and processed and automated over 1.1 billion expense transactions on the platform. For the quarter ended June 30, 2021, an average of 639,000 paid members across 53,000 companies and over 200 countries and territories used Expensify to make money easy. $Paragon 28(FNA.US)$, founded in 2010, is a medical device company exclusively focused on the foot and ankle orthopedic market. It provides a comprehensive portfolio of solutions that includes surgical implants and disposables, as well as surgical instrumentation. The company's suite of surgical solutions comprises 72 product systems, including approximately 8,700 SKUs to help fit the specific needs of each patient and procedure. It designs each products with the goal of improving outcomes, reducing ailment recurrence and complication rates, and making the procedures simpler, consistent and reproducible. $TaskUs(TASK.US)$is a digital outsourcer, focused on serving high-growth technology companies to represent, protect and grow their brands. It provides customer support services to fast-growing tech companies including Uber, Netflix, Coinbase and Zoom. Employees are spread across eight countries, and TaskUs dedicates hundreds or even thousands of staffers to its top clients so it can handle all their support-related issues. Revenue climbed 33% last year to $478 million, and TaskUs is profitable, showing annual net income of $34.5 million last year. As of October 17th, it has a listed-to-date return of181.57%, with a market cap of $6.30billion.
Paragon 28股票討論區
On the last trading day, there were five traditional IPO filed, while one new stock officially was listed for trading.
Medical device company Paragon 28 started trading yesterday. It soared 16.94% in its NYSE debut and was valued at $1.41 billion.
Cloud-based expense management software platform $Expensify(EXFY.US)$ , based in Portland, Oregon, helps the smallest to the largest businesses simplify the way they manage money.
Since its founding in 2008, it has added over 10 million members to the community, and processed and automated over 1.1 billion expense transactions on the platform.
For the quarter ended June 30, 2021, an average of 639,000 paid members across 53,000 companies and over 200 countries and territories used Expensify to make money easy.
$Paragon 28(FNA.US)$ , founded in 2010, is a medical device company exclusively focused on the foot and ankle orthopedic market.
It provides a comprehensive portfolio of solutions that includes surgical implants and disposables, as well as surgical instrumentation. The company's suite of surgical solutions comprises 72 product systems, including approximately 8,700 SKUs to help fit the specific needs of each patient and procedure.
It designs each products with the goal of improving outcomes, reducing ailment recurrence and complication rates, and making the procedures simpler, consistent and reproducible.
$TaskUs(TASK.US)$ is a digital outsourcer, focused on serving high-growth technology companies to represent, protect and grow their brands.
It provides customer support services to fast-growing tech companies including Uber, Netflix, Coinbase and Zoom.
Employees are spread across eight countries, and TaskUs dedicates hundreds or even thousands of staffers to its top clients so it can handle all their support-related issues.
Revenue climbed 33% last year to $478 million, and TaskUs is profitable, showing annual net income of $34.5 million last year.
As of October 17th, it has a listed-to-date return of181.57%, with a market cap of $6.30billion.
GitLab IPO: 5 things to know about the $8 billion valued all-remote software company
$Gitlab(GTLB.US)$ $AvidXchange(AVDX.US)$ $Augmedix(AUGX.US)$ $Cingulate(CING.US)$ $Lucid Diagnostics(LUCD.US)$ $IHS Holding(IHS.US)$ $Paragon 28(FNA.US)$
暫無評論